Your browser doesn't support javascript.
A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of Coronavirus disease
Journal of Drug Delivery and Therapeutics ; 11(1):121-129, 2021.
Article in English | CAB Abstracts | ID: covidwho-1409925
ABSTRACT
The coronavirus disease has spread all over the world. Till now no medicine, vaccine, and any other monoclonal antibodies have been approved for the diagnosis or prevention of COVID-19. In many countries, doctors are considering "repurposing" different approved drugs like interferon-a, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, etc. to treat COVID-19. Remedesivir (GS-5734) is a prodrug of monophosphoramidate of adenosine analogue. Remedesivir block the viral RNA dependent RNA polymerease (RdRp). Favipiravir (T-705) is also a prodrug and was revealed during evaluating the antiviral activity of chemical agents concerning the influenza virus. This review summarizes the status, mechanisms, preclinical research, and clinical trial progress of remedesivir and favipiravir for the treatment of COVID-19.

Full text: Available Collection: Databases of international organizations Database: CAB Abstracts Type of study: Prognostic study Language: English Journal: Journal of Drug Delivery and Therapeutics Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: CAB Abstracts Type of study: Prognostic study Language: English Journal: Journal of Drug Delivery and Therapeutics Year: 2021 Document Type: Article